Anti-inflammatory compounds, pharmaceutical compositions, and methods of treating hemochromatosis, and other disorders
AssigneeMiralogx LLC
InventorJonnie R. Williams
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compounds have anti-inflammatory activity. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. A method of treating hemochromatosis, hyperammonemia, or a disorder associated with chronic inflammation or a cancer, involves administering the pharmaceutical composition to an individual in need thereof. In another aspect, a method of inhibiting formation of metal oxides or reducing metal reactivity comprises contacting a metal with an effective amount of the compound(s).
Claims20
A compound having a structure according to Formula Ia or Formula Ib set forth below:
- or a pharmaceutically acceptable ester or solvate thereof, wherein X− is an ion of an acid forming a pharmaceutically acceptable salt, wherein R1, R2, R4, R5, R6, R7, and R8 are independently selected from the group consisting of nothing, H, OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, and heterocycle;
- wherein the alkyl, alkenyl, alkynyl or acyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle;
- wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl;
- wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl;
- wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl, and wherein represents a single bond or a double bond with the proviso that within a five-membered ring, one is a single bond and the other is a double bond.
A compound having a structure according to Formula Ia or Formula Ib set forth below:
- or a pharmaceutically acceptable ester or solvate thereof, wherein X− is an ion of an acid forming a pharmaceutically acceptable salt, where A1, A2, A3, and A4 are independently selected from nitrogen and carbon, wherein R1, R2, R3, R4, R5, R6, R7, and R8 are independently selected from the group consisting of nothing, H, OH, protected hydroxyl, alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, and heterocycle;
- wherein R1 is nothing if A3 is N;
- wherein R3 is nothing if A4 is N;
- wherein the alkyl, alkenyl, alkynyl or acyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, NRARB, —S-alkyl, —SO-alkyl, —SO2-alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycle;
- wherein RA and RB are each independently selected from hydrogen and C1-4 alkyl;
- wherein the aryl or heteroaryl, whether alone or as part of a substituent group, is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OH, alkyl, —O-alkyl, —COOH, —C(O)—C1-4 alkyl, —C(O)O—C1-4 alkyl, NRCRD, —S-alkyl, —SO-alkyl and —SO2-alkyl;
- wherein RC and RD are each independently selected from hydrogen and C1-4 alkyl;
- wherein represents a single bond or a double bond with the proviso that within a five-membered ring, one is a single bond and the other is a double bond;
- and wherein R2 and/or R4 has the structure according to Formula IIa or Formula IIb:
- wherein X−, A1, A2, R5, R6, R7, and R8 are defined as above.
(canceled)
A compound having a structure selected from the group consisting of:
- or a pharmaceutically acceptable salt or solvate thereof.
(canceled)
Dependencies are inferred from the claim text.